Association Between Plasma Vitamin D2 and Type 2 Diabetes Mellitus

Abstract

ObjectiveTo investigate the relationship between plasma vitamin D2(VD2) and type 2 diabetes(T2DM).MethodData from electronic medical records of 797 inpatients treated at Sun Yat Sen Memorial Hospital, Sun Yat-sen University between June 24, 2019 and December 24, 2020 were collected, and a total of 596 patients were enrolled after screening based on inclusion and exclusion criteria. Patients were divided into diabetic and non-diabetic groups according to whether they had T2DM. The Wilcoxon rank sum test was finally selected for the analysis of differences between groups according to the distribution of patients’ plasma VD2, and logistic regression models were used to find the corresponding influencing factors.ResultOf the 596 hospitalized patients, 138 (23.15%) were diagnosed with T2DM. The Wilcoxon test showed no statistically significant difference in plasma VD2 concentrations between the T2DM and non-T2DM groups (p=0.833). After adjustment for confounders by multivariate logistic regression, there was still no significant difference in plasma VD2 concentrations between the two groups (P=0.316, OR: 1.15 (0.88,1.49)). The uncorrelated relationship between VD2 and T2DM was not found to change after incorporating 12 indicators, including demographic characteristics, laboratory indicators and complications, into the logistic regression model by 3 steps, even the OR (1.08 (0.92,1.26)) did not change in the 3 models. Similarly, the adjusted ORs agreed that there was no statistical association between VD2 and T2DM.ConclusionVD2 levels are similar in patients with T2DM compared to those without T2DM. Clinical caution should be exercised in giving VD2 supplementation to patients with T2DM unless other diseases requiring VD2 supplementation (e.g., rickets, osteoporosis) are present.

The Effect of Vitamin D Supplementation on Incidence of Type 2 Diabetes: A Systematic Review

“…In another study by Qi et al, wherein 138 of the 596 subjects developed T2DM, showed that there was no statistical significance in vitamin D concentrations between those that developed T2DM versus those that did not develop the disease. Despite adjusting for confounders, the findings were consistent [ 28 ]. Lastly, going further via genetic analysis found that there was no association between a genetic predisposition from an increase in the levels of 25(OH)D and the risk of developing T2DM in a cohort of European descent.…”

Five blueberry anthocyanins and their antioxidant, hypoglycemic, and hypolipidemic effects in vitro

“…The BBA was further purified by the octadecylsilyl (ODS) column using MeOH/H 2 O (containing 0.1% formic acid) in a gradient manner to obtain 16 fractions (Frs. [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16]. The desired fractions were purified by preparative HPLC (ODS-AQ, 200 × 20 mm, 5 µm).…”

“…Increased adiposity, which is frequently associated with multiple chronic comorbidities, is looked at as the strongest risk factor for developing type 2 diabetes mellitus (T2DM) ( 2 ). According to the International Diabetes Federation (IDF), the global diabetic patients aged 20–79 years are estimated to be 536.6 million in 2021, of which T2DM accounts for approximately 90% of the total ( 3 ). “Diabesity” is a term used to describe the combined detrimental health effects of T2DM and obesity/overweight ( 4 ).…”

Clarifying the Heterogeneity in Response to Vitamin D in the Development, Prevention, and Treatment of Type 2 Diabetes Mellitus: A Narrative Review

“…The literature concerning vitamin D (VitD) supplementation in the prevention, treatment, and remission of type 2 diabetes mellitus (T2DM) spans decades, is complex, and is often contradictory with authors reporting mixed findings upon intervention with ergocalciferol (VitD2) or cholecalciferol (VitD3) (either alone or in combination with other agents such as calcium and fish oil [1][2][3][4]). This is also true of the epidemiological literature, including a negative Mendelian randomization analysis in a Chinese population [5][6][7]. There likely exist a litany of factors contributing to this heterogeneity, such as trial design, baseline VitD status, variability in VitD metabolism, ethnicity, administered VitD dose, BMI, and nutritional status.…”